PATRICK DEVAL L - 05 Jun 2024 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role: Director
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 05 Jun 2024
Net transactions value: $0
Form type: 4
Filing time: 07 Jun 2024, 16:34:15 UTC
Previous filing: 19 Mar 2024
Next filing: 10 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Award		+10,461	+319%		13,743	05 Jun 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company.

Content

The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company.